Stephen George Dilly, See Remarks at Aimmune Therapeutics, Inc. (AIMT), sold 199,900 shares at $35.39 ($6.7M) on 2017-10-23, disclosed to the SEC on 2017-10-25.
Open-market sale of $6.7M AIMT by See Remarks. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $33.23 | 75,468 | $2.5M | 37.4% |
| 2 | $33.23 | 75,468 | $2.5M | 37.4% |
| 3 | $34.15 | 17,472 | $597K | 8.9% |
| 4 | $34.15 | 17,472 | $597K | 8.9% |
| 5 | $35.39 | 6,960 | $246K | 3.7% |
| 6 | $35.39 | 6,960 |
| $246K |
| 3.7% |
| 7 | $36.55 | 100 | $4K | 0.1% |
| Total | $33.54 avg | 199,900 | $6.7M | 100% |
| Filing → |
| SRRA | BUY | 2021-05-20 | $178K | — | Filing → |
| SGMO | SELL | 2020-03-20 | $210K | — | Filing → |
| SGMO | SELL | 2020-03-18 | $90K | — | Filing → |